Overexpression of TROP2 (trophoblast cell surface antigen 2) in advanced gastric cancer has been identified as a poor prognostic factor. SKB264 (MK-2870) is a TROP2 ADC (Antibody-Drug Conjugate) designed with a unique linker to attach the payload, a belotecan-derivative topoisomerase I inhibitor. This linker underg...
Find MoreASTX295 is a novel small molecule antagonist of human Murine Double Minute 2 (MDM2), which tightly regulates the level and activity of the p53 tumor suppressor. According to the data presented at the AACR 2024 conference, the study enrolled 83 participants across 14 cohorts, investigating various dosing regimens an...
Find MoreTriple-negative breast cancer (TNBC) accounts for 15–20% of incident breast cancers and is the only breast cancer (BC) subtype lacking targeted treatments. It is a biologically aggressive tumor characterized by moderate/high grade and highly proliferative cancer cells, which, together with limited treatment options...
Find MoreAt the American Association for Cancer Research (AACR) Annual Meeting 2024, significant findings from the Phase I/II PETRA trial, led by researchers at The University of Texas MD Anderson Cancer Center, were presented. The trial focused on evaluating the first-in-class PARP1-selective inhibitor, saruparib, in patie...
Find MoreP-BCMA-ALLO1 is a novel investigational BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor T-cell (CAR-T) therapy manufactured from healthy donor T-cells and available off-the-shelf. The findings presented at the AACR 2024 demonstrated that around 60% of patients (3 out of 5) with RR...
Find MoreThe treatment landscape for locally advanced Head and Neck Squamous Cell Carcinoma (HNSCC) presents a challenge, with conventional approaches such as surgery, radiation, and chemotherapy offering modest success rates. Despite these interventions, less than half of patients achieve disease-free status at 2 years, an...
Find MoreNon-melanoma skin cancer (NMSC) is the most common post-transplant malignancy in solid organ transplant (SOT) recipients and occurs at a 7–53x higher incidence vs. the general population. Additionally, the optimal management of NMSC in SOT is not well established. RP1 is an oncolytic immunotherapy (HSV-1) that expr...
Find MoreRegeneron Pharmaceuticals unveiled promising results from the Phase I/II LINKER-MM1 trial of linvoseltamab in patients grappling with relapsed/refractory (R/R) multiple myeloma (MM) during the oral plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego. Linvoselta...
Find MoreCancer vaccines represent a novel approach in cancer treatment, leveraging the body's immune system to identify and eradicate cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines aim to stimulate an immune response against specific proteins found on cancer cells, potentially p...
Find MoreNectin-4, despite being a well-established oncology target, is currently underutilized in drug development compared to HER2, TROP2, and Claudin18.2. However, its significant potential is underscored by its prevalent overexpression in various cancer types, such as pancreatic, ovarian, cervical, head-and-neck, breast...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.